<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>UNLABELLED: Pervious biochemical and hemodynamic studies have highlighted the important role of εPKC in cardioprotection during ischemic preconditioning </plain></SENT>
<SENT sid="1" pm="."><plain>However, little is known about the electrophysiological consequences of εPKC modulation in ischemic hearts </plain></SENT>
<SENT sid="2" pm="."><plain>Membrane permeable <z:chebi fb="7" ids="16670">peptide</z:chebi> εPKC selective activator and inhibitor were used to investigate the role of εPKC modulation in reperfusion <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Protein transduction domain from HIV-TAT was used as a carrier for <z:chebi fb="7" ids="16670">peptide</z:chebi> delivery into intact Langendorff perfused guinea pig hearts </plain></SENT>
<SENT sid="4" pm="."><plain>Action potentials were imaged and mapped (124 sites) using optical techniques and surface ECG was continuously recorded </plain></SENT>
<SENT sid="5" pm="."><plain>Hearts were exposed to 30 min stabilization period, 15 min of no-flow <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, followed by 20 min reperfusion </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="7" ids="16670">Peptides</z:chebi> (0.5 μM) were infused as follows: (a) control (vehicle-TAT <z:chebi fb="7" ids="16670">peptide</z:chebi>; TAT-scrambled ψεRACK <z:chebi fb="7" ids="16670">peptide</z:chebi>); (b) εPKC <z:chebi fb="4" ids="48705">agonist</z:chebi> (TAT-ψεRACK); (c) εPKC <z:chebi fb="68" ids="48706">antagonist</z:chebi> (TAT-εV1) </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Hearts treated with εPKC <z:chebi fb="4" ids="48705">agonist</z:chebi> ψεRACK had reduced incidence of <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> (VT, 64%) and <z:mp ids='MP_0006109'>fibrillation</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>, 50%) compared to control (VT, 80%, P&lt;0.05) and (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>, 70%, P &lt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>However, the highest incidence of VT (100%, P &lt; 0.05) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> (80%) occurred in hearts treated with εPKC <z:chebi fb="68" ids="48706">antagonist</z:chebi> <z:chebi fb="7" ids="16670">peptide</z:chebi> εV1 compared to control and to εPKC <z:chebi fb="4" ids="48705">agonist</z:chebi> ψεRACK </plain></SENT>
<SENT sid="9" pm="."><plain>Interestingly, at 20 min reperfusion, 100% of hearts treated with εPKC <z:chebi fb="4" ids="48705">agonist</z:chebi> ψεRACK exhibited complete recovery of action potentials compared to 40% (P &lt; 0.05) of hearts treated with εPKC <z:chebi fb="68" ids="48706">antagonist</z:chebi> <z:chebi fb="7" ids="16670">peptide</z:chebi>, εV1 and 65% (P &lt; 0.5) of hearts in control </plain></SENT>
<SENT sid="10" pm="."><plain>At 20 min reperfusion, maps of action potential duration from εPKC <z:chebi fb="4" ids="48705">agonist</z:chebi> ψεRACK showed minimal dispersion (48.2 ± 9 ms) compared to exacerbated dispersion (115.4 ± 42 ms, P &lt; 0.05) in εPKC <z:chebi fb="68" ids="48706">antagonist</z:chebi> and control (67 ± 20 ms, P&lt;0.05) </plain></SENT>
<SENT sid="11" pm="."><plain>VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> and dispersion from hearts treated with scrambled <z:chebi fb="4" ids="48705">agonist</z:chebi> or <z:chebi fb="68" ids="48706">antagonist</z:chebi> <z:chebi fb="7" ids="16670">peptides</z:chebi> were similar to control </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: The results demonstrate that εPKC activation by ψεRACK <z:chebi fb="7" ids="16670">peptide</z:chebi> protects intact hearts from reperfusion <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> and affords better recovery </plain></SENT>
<SENT sid="13" pm="."><plain>On the other hand, inhibition of εPKC increased the incidence of <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> and worsened recovery compared to controls </plain></SENT>
<SENT sid="14" pm="."><plain>The results carry significant therapeutic implications for the treatment of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">ischemic heart disease</z:e> by preconditioning-mimicking agents </plain></SENT>
</text></document>